Animol Discovery, Inc. Announces Series B Financing of $34.0 million to Advance Its Pipeline of Novel Veterinary Pharmaceuticals
28.7.2022 14:07:00 EEST | Business Wire | Press release
Animol Discovery, Inc., a pioneer in veterinary pharmaceutical discovery, today announced it has raised $34.0 million in Series B financing. The investment was led by Novalis Lifesciences, with participation from Finistere Ventures and existing investor Anterra Capital. The proceeds allow the company to expand and advance its pipeline of novel active pharmaceutical ingredients through clinical development and further enhance its cutting-edge drug discovery platform.
The $40Bn animal health industry continues to demand novel medicines to treat infectious and chronic diseases in companion and production animals. Recent successes, such as Apoquel™ from Zoetis and Nexguard™ from Boehringer Ingelheim, demonstrate the potential to build towards blockbuster franchises in the sector with novel pharmaceutical products.
“Pet parents and livestock farmers continue to demand novel veterinary pharmaceuticals that can protect animals against diseases and improve quality of life,” said Andrew Plant PhD, chief executive officer, Animol Discovery. “Despite this strong demand, innovation is lagging. At Animol, we seek to address this innovation gap by leveraging the most advanced tools from human pharma to bring forward a wealth of new medicines that can benefit animals and the people who care for them.”
Founded in 2020 and incubated by Anterra Capital, Animol is pioneering the use of DNA Encoded Library (DEL) drug discovery technology coupled with powerful machine learning approaches to enable the rapid discovery of novel veterinary medicines.
“We have built Animol on the same cutting edge discovery techniques that we are using to disrupt drug discovery in human pharma (ZebiAI - acquired by Relay Therapeutics) and crop protection (Enko Chem),” said Philip Austin, Managing Partner at Anterra Capital. “Translating these tools to the massive opportunity available in veterinary pharma was the next obvious step and we are already seeing their use successfully build into a rich pipeline of promising compounds.”
Animol also announced that Marijn Dekkers PhD, founder & chairman of Novalis LifeSciences LLC will join the Board of Directors. Dr. Dekkers formerly served as the CEO of Bayer AG, and as the CEO of Thermo Fisher Scientific, Inc. At Bayer he oversaw one of the largest global animal health companies.
“Most current medicines in the $40B veterinary pharma market are derived from drugs that have been originally developed for humans. There is of course nothing wrong with that, but there are many animal-specific diseases that require a targeted effort. I like Animol Discovery’s approach to use its breakthrough drug discovery platform to specifically address significant unmet needs in animals. I am looking forward to working with the team to optimize the opportunity ahead,” said Dr. Dekkers.
“It is a great pleasure to be able to welcome Marijn Dekkers to our Board of Directors. Dr. Dekkers is an exceptional industry leader with a track record of turning innovation into successful businesses across the spectrum of life sciences, including in animal health,” said Andrew Plant PhD, chief executive officer, Animol Discovery. “He is an excellent addition to our team of experienced industry leaders.”
“I am also delighted to bring Doug Hutchens on board as chief scientific officer. Dr. Hutchens brings a wealth of industry experience in animal health research and product development; having someone who has also served as Chief Veterinary Officer within a major animal health company brings huge value to our expanding team,” added Dr. Plant.
“I am thrilled by the prospect of joining Animol’s dynamic and experienced team as chief scientific officer,” said Doug Hutchens, DVM, PhD. “The company’s ability to interrogate protein targets with billions of DNA-tagged molecules and, using DNA sequencing, identify selective inhibitors from numerous diverse chemical families is game changing in animal health drug discovery. Leveraging these data with proprietary, highly predictive machine learning algorithms, is enabling the identification of novel drug-like compounds in a matter of weeks from the initial DEL screen. This technology platform greatly expands the opportunities, significantly increases the probability, and accelerates the timeline in developing new classes of therapeutic molecules.”
About Animol
Animol is a pioneer in using state of the art drug discovery technology to discover small molecule active pharmaceutical ingredients to transform standards of care in veterinary medicine. The company is reducing the time and cost to discover novel active ingredients utilizing DNA-encoded libraries, machine learning/AI and structure-based design.
Animol is a private company based in Boston, Massachusetts. For more information see www.Animol-discovery.com
About Novalis LifeSciences LLC
Novalis LifeSciences LLC is an investment and advisory firm for the Life Science industry that was founded in 2017 by Marijn E. Dekkers. With a team of experienced operating executives from the Life Science industry, Novalis funds and advises visionary Life Science entrepreneurs. In addition to making financial investments, Novalis provides strategic and operational advice to portfolio companies that are at a critical growth stage in their development. For more information, visit www.novalislifesciences.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005186/en/
Contact information
Dr. Andrew Plant
CEO
Animol Discovery, Inc.
andrew.plant@animol-discovery.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The LYCRA Company to Eliminate More than $1.2 Billion of Debt through Prepackaged Restructuring Process, Positioning Business for Long-Term Financial Stability and Growth17.3.2026 09:51:00 EET | Press release
The LYCRA Company, LLC (“LYCRA” or “the Company”), a global leader in developing fiber and technology solutions for the apparel and personal care industries, announced today that it has entered into a restructuring support agreement (“RSA”) with the overwhelming majority of its creditors to eliminate approximately $1.2 billion of long-term debt and establish a sustainable capital structure that will recapitalize the Company and position it for long-term financial stability and growth. The RSA has overwhelming support from holders of the Company’s senior secured term loan, 16.000% Senior Secured Notes, and 7.500% Senior Secured Notes, who have agreed to vote in favor of a prepackaged plan of reorganization (the “Prepackaged Plan”). To implement the Prepackaged Plan, the Company and certain of its affiliates, have filed a voluntary prepackaged Chapter 11 case in the U.S. Bankruptcy Court for the Southern District of Texas. The Prepackaged Plan reflects a consensual agreement reached over
EIG’s MidOcean Energy Announces Initial Equity Raise of $1.2 billion Versus $1.0 billion Cover17.3.2026 09:26:00 EET | Press release
MidOcean Energy (“MidOcean” or the “Company”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced an equity capital raise of more than $1.2 billion. This equity raise includes: a $500 million commitment from Idemitsu Kosan, a highly respected global energy company with a long-standing presence across the energy value chain; and additional commitments of $790 million from both new and existing investors. This represents a significant milestone in MidOcean’s capital formation program and reflects continued interest from both new and existing investors in the Company’s strategy to seek to build a diversified, resilient, long-life global LNG platform. There is significant further momentum from additional investors currently in documentation. MidOcean will continue to raise capital, with a cumulative target of up to $2 billion from new investors. The Company has received substantial interest from investors seeking long-term exposure to the LNG sector, supported
RS2 Launches “Beyond by RS2” to Power the Next Generation of European Fintech17.3.2026 09:00:00 EET | Press release
RS2, a Tier-1 global provider of payment processing infrastructure and technology solutions, today announced the launch of Beyond by RS2, a new digital payments brand designed to help fintech companies, platforms, and payment providers rapidly launch card issuing and payment acceptance services across Europe. Built on RS2’s globally proven BankWORKS platform, Beyond by RS2 offers fintechs a comprehensive sponsored issuer and acquiring program, enabling partners to issue cards and process payments without needing their own banking license or direct card scheme membership. The program leverages RS2’s Electronic Money Institution (EMI) license in Germany and its principal membership with Visa and Mastercard, allowing fintech partners to operate under RS2’s regulated infrastructure while maintaining their own customer experience and brand. “Beyond by RS2 represents a major step in our strategy to enable innovation in payments,” said Radi El Haj, CEO, RS2. “Fintechs today want to build powe
H2SITE Appoints Javier Cavada as New Chairman of the Board of Directors17.3.2026 08:00:00 EET | Press release
H2SITE, a technology company delivering hydrogen production and separation solutions, announces the appointment of Javier Cavada as the new Chairman of the Board of Directors. Javier joins H2SITE at a strategic phase of accelerated industrial deployment and scale-up of its hydrogen solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316654723/en/ With more than 25 years of international leadership in the energy and industrial sectors, Javier brings extensive experience in industrialising complex technologies, building high-performance organisations, and scaling large-scale energy platforms. He currently serves as President and Chief Executive Officer of Mitsubishi Power EMEA. His track record also includes serving as CEO and President of Highview Power, as well as spending 17 years at Wärtsilä Corporation, where he held senior executive roles including President of the Energy division and a member of the global Exec
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies17.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics portfolio, alongside three symposia, and multiple Masterclasses and Meet‑the‑Expert sessions, all highlighting the expanding benefits of Sculptra, Relfydess and the Restylane range.1-9 This comprehensive scientific presence reflects Galderma’s holistic, trend‑led approach to innovation, and its commitment to addressing emerging needs such as menopause‑related skin changes, the growing interest in regenerative treatments, and the rising demand for body injectables. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316497387/en/ “Patients’ needs are changing faster than ever, whether that’s navigating the skin changes associated with menopause, seeking regenerative benefits, or looking for aesthetic harmony beyond the face. The data
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom